JP2015535243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535243A5 JP2015535243A5 JP2015539556A JP2015539556A JP2015535243A5 JP 2015535243 A5 JP2015535243 A5 JP 2015535243A5 JP 2015539556 A JP2015539556 A JP 2015539556A JP 2015539556 A JP2015539556 A JP 2015539556A JP 2015535243 A5 JP2015535243 A5 JP 2015535243A5
- Authority
- JP
- Japan
- Prior art keywords
- melphalan flufenamide
- flufenamide hydrochloride
- lyophilized pharmaceutical
- sucrose
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YQZNKYXGZSVEHI-VXKWHMMOSA-N ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 YQZNKYXGZSVEHI-VXKWHMMOSA-N 0.000 claims 35
- 229950009924 melphalan flufenamide Drugs 0.000 claims 23
- 229930006000 Sucrose Natural products 0.000 claims 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000005720 sucrose Substances 0.000 claims 15
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical group CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 14
- 239000000243 solution Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719184P | 2012-10-26 | 2012-10-26 | |
| SE1251211 | 2012-10-26 | ||
| SE1251211-7 | 2012-10-26 | ||
| US61/719,184 | 2012-10-26 | ||
| PCT/SE2013/051246 WO2014065751A1 (en) | 2012-10-26 | 2013-10-24 | Lyophilized preparations of melphalan flufenamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535243A JP2015535243A (ja) | 2015-12-10 |
| JP2015535243A5 true JP2015535243A5 (enExample) | 2016-11-10 |
| JP6284945B2 JP6284945B2 (ja) | 2018-02-28 |
Family
ID=50544986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539556A Active JP6284945B2 (ja) | 2012-10-26 | 2013-10-24 | メルファランフルフェナミドの凍結乾燥製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10285946B2 (enExample) |
| EP (2) | EP2928463B1 (enExample) |
| JP (1) | JP6284945B2 (enExample) |
| KR (1) | KR102205592B1 (enExample) |
| CN (2) | CN104994847B (enExample) |
| AU (1) | AU2013335359B2 (enExample) |
| BR (1) | BR112015009280B1 (enExample) |
| CA (1) | CA2889753C (enExample) |
| CY (1) | CY1122483T1 (enExample) |
| IL (1) | IL238398B (enExample) |
| MX (1) | MX365205B (enExample) |
| NZ (1) | NZ708016A (enExample) |
| PL (1) | PL2928463T3 (enExample) |
| RS (1) | RS60068B1 (enExample) |
| RU (1) | RU2643762C2 (enExample) |
| SI (1) | SI2928463T1 (enExample) |
| SM (1) | SMT202000058T1 (enExample) |
| WO (1) | WO2014065751A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2701720T3 (en) | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| IL277469B2 (en) | 2018-03-29 | 2024-11-01 | Airway Therapeutics Inc | Systems and methods for characterizing surfactant protein d (sp-d) oligomers |
| JP7797098B2 (ja) | 2018-03-29 | 2026-01-13 | エアウェイ・セラピューティクス・インコーポレイテッド | サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物 |
| US12152087B2 (en) * | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| WO2020201542A1 (en) | 2019-04-03 | 2020-10-08 | Oncopeptides Ab | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| JP2024524552A (ja) | 2021-07-08 | 2024-07-05 | オンコペプティデス エービー | 多発性骨髄腫の治療に使用するためのメルフルフェン |
| KR102757193B1 (ko) * | 2021-10-19 | 2025-01-21 | 단국대학교 천안캠퍼스 산학협력단 | 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727157D0 (en) | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| DE60141398D1 (de) * | 2000-06-13 | 2010-04-08 | Oncopeptides Ab | Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs |
| SE0002202D0 (sv) * | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| WO2003035030A1 (en) * | 2001-10-24 | 2003-05-01 | Pari Gmbh | Kit for the preparation of a pharmaceutical composition |
| US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| KR101143596B1 (ko) * | 2006-07-07 | 2012-05-11 | 길리애드 사이언시즈, 인코포레이티드 | 신규의 피리다진 화합물 및 이의 용도 |
| DK2101731T3 (en) * | 2006-11-21 | 2018-04-16 | Jina Pharmaceuticals Inc | ENDOXIFEN FOR USING CANCER TREATMENT |
| CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
| WO2011078782A1 (en) | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| HRP20201241T1 (hr) | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| DK2701720T3 (en) * | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
-
2013
- 2013-10-24 SM SM20200058T patent/SMT202000058T1/it unknown
- 2013-10-24 JP JP2015539556A patent/JP6284945B2/ja active Active
- 2013-10-24 NZ NZ708016A patent/NZ708016A/en unknown
- 2013-10-24 RU RU2015118581A patent/RU2643762C2/ru active
- 2013-10-24 EP EP13849763.1A patent/EP2928463B1/en active Active
- 2013-10-24 RS RS20200116A patent/RS60068B1/sr unknown
- 2013-10-24 KR KR1020157013026A patent/KR102205592B1/ko active Active
- 2013-10-24 MX MX2015005217A patent/MX365205B/es active IP Right Grant
- 2013-10-24 SI SI201331667T patent/SI2928463T1/sl unknown
- 2013-10-24 CN CN201380063592.5A patent/CN104994847B/zh active Active
- 2013-10-24 BR BR112015009280-2A patent/BR112015009280B1/pt active IP Right Grant
- 2013-10-24 CA CA2889753A patent/CA2889753C/en active Active
- 2013-10-24 WO PCT/SE2013/051246 patent/WO2014065751A1/en not_active Ceased
- 2013-10-24 CN CN201810826176.0A patent/CN108685860B/zh active Active
- 2013-10-24 AU AU2013335359A patent/AU2013335359B2/en not_active Ceased
- 2013-10-24 EP EP19207842.6A patent/EP3628318A1/en active Pending
- 2013-10-24 PL PL13849763T patent/PL2928463T3/pl unknown
- 2013-10-24 US US14/438,473 patent/US10285946B2/en active Active
-
2015
- 2015-04-21 IL IL238398A patent/IL238398B/en active IP Right Grant
-
2016
- 2016-05-09 US US15/149,975 patent/US10285947B2/en active Active
-
2020
- 2020-01-13 CY CY20201100028T patent/CY1122483T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535243A5 (enExample) | ||
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| WO2016184576A3 (en) | Dry powder composition comprising long-chain rna | |
| JP2016510326A5 (enExample) | ||
| JP2014077003A5 (enExample) | ||
| UA114907C2 (uk) | Гетероциклільні сполуки як інгібітори mek | |
| HRP20221355T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| JP2017531619A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| PH12017550152A1 (en) | Lyophilized pharmaceutical compositions | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015078220A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2014525449A5 (enExample) | ||
| JP2017532343A5 (enExample) | ||
| RU2017123880A (ru) | Антагонисты миостатина или активина для лечения саркопении | |
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| PH12020550041A1 (en) | Drug compound and purification methods thereof | |
| RU2016127558A (ru) | Стероидное соединение для применения в лечении печеночной энцефалопатии | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| JP2018538308A5 (enExample) | ||
| WO2016184577A3 (en) | Dry powder composition comprising long-chain rna |